Floatz logo

Therapeutic Asset Ratings

119 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
abn401
Neoplasms
Yonsei UniversityP2CCC (52)
Absk043
Neoplasms
Abbisko Therapeutics Co, LtdP2CCC (52)
Adebrelimab
Neoplasms
Beidahuang Industry Group General HospitalP2CCC (52)
Arimidex
Neoplasms
DR. DIANE CHISESI NFS. MD. PHD.P2CCC (52)
Letetresgene Autoleucel
Neoplasms
USWM CT, LLCP2CCC (52)
Pomalidomide
Neoplasms
Hellenic Society of HematologyP2CCC (52)
Sargramostim
Neoplasms
Partner Therapeutics, Inc.P2CCC (52)
Gdc-0449
Neoplasms
Helsinki University Central HospitalP2CCC (51)
ASCRINVACUMAB
Neoplasms
Suzhou Kintor Pharmaceutical Inc,P1/2CCC (49)
Entinostat
Neoplasms
University Hospital HeidelbergP1/2CCC (49)
[18f]rccb6
Neoplasms
RenJi HospitalP2CCC (48)
Adapt-001
Neoplasms
EpicentRx, Inc.P2CCC (48)
g207
Neoplasms
Pediatric Brain Tumor ConsortiumP2CCC (48)
GSK3377794
Neoplasms
USWM CT, LLCP2CCC (48)
Isatuximab
Neoplasms
Hellenic Society of HematologyP2CCC (48)
NKT2152
Neoplasms
NiKang Therapeutics, Inc.P2CCC (48)
PANITUMUMAB
Neoplasms
Blokhin's Russian Cancer Research CenterP2CCC (48)
RANITIDINE
Neoplasms
Hellenic Society of HematologyP2CCC (48)
Slc-3010
Neoplasms
Yonsei UniversityP2CCC (48)
Triadeno Vaccine
Neoplasms
National Cancer Institute (NCI)P2CCC (48)
VIPIVOTIDE TETRAXETAN
Neoplasms
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupP2CCC (48)
bi 907828
Neoplasms
Boehringer IngelheimP1CCC (48)
n-803
Neoplasms
National Cancer Institute (NCI)P2CC (47)
Chimeric Antigen Receptor Modified T Cells Infusion
Neoplasms
UNC Lineberger Comprehensive Cancer CenterP1/2CC (46)
Ris-Rez
Neoplasms
GlaxoSmithKlineP1/2CC (46)
Showing 26 to 50 of 119 assets
PreviousPage 2 of 5Next